- CH₣240.95bn
- CH₣273.64bn
- $56.33bn
Table: Swiss trade surplus at CHF 3.098 bln in April
Swiss stocks - Factors to watch on June 1
Experimental Novartis radiopharma drug shows promise in early study
Brief: Novartis' Pluvicto™ Demonstrated Consistent Efficacy Across Key Patient Subgroups In Metastatic Hormone-Sensitive Prostate Cancer
China's commerce ministry holds meeting with foreign pharmaceutical firms
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy
Brief: Novartis: Pluvicto Psmaddition Data To Highlight Efficacy In Metastatic Hormone-Sensitive Prostate Cancer
US Supreme Court rebuffs pharma challenge to Biden-era drug price
Brief: Novartis - Data Shows 58% Lower Risk Of Psa Progression With Pluvicto In Prostate Cancer
Health Rounds: Common ADHD medicines help treat cancer-related fatigue
Brief: Novartis AG - Denton Site Expected To Be Operational In 2028 And Create New Us Jobs
Bayer's experimental blood thinner cuts risk and severity of repeat strokes (updated)
Novartis to cut 220 jobs as it closes German site (updated)
Novartis to cut 220 jobs as it closes German site
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Swiss stocks - Factors to watch on May 4
Brief: Novartis Receives Health Canada Approval For Fabhalta Oral Treatment For Adults With C3G
Judge at drug industry's urging blocks North Dakota discounted medications law